Caribou Biosciences, Inc. (CRBU) Current Ratio
- Current ratio · latest quarter: Value 6.49×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.49× | Current assets / current liabilities. $116.59M ÷ $17.97M ≈ 6.49× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 116.59M USD | Assets, Current |
| Current obligations | 17.97M USD | Liabilities, Current |
| Cash and equivalents | 26.19M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 86.12M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | 203.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 3.08M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $116.59M | $17.97M | $26.19M | $86.12M | $203.00K | (m) | $3.08M | (m) | 6.49× |
| 2026-03-31 | $122.38M | $19.67M | $12.06M | $105.57M | $227.00K | (m) | $3.50M | (m) | 6.22× |
| 2025-12-31 | $145.23M | $25.41M | $12.36M | $126.98M | $69.00K | (m) | $5.78M | (m) | 5.71× |
| 2025-09-30 | $155.51M | $28.06M | $11.14M | $136.12M | $242.00K | (m) | $3.80M | (m) | 5.54× |
| 2025-06-30 | $192.51M | $28.89M | $25.20M | $158.75M | $71.00K | (m) | $3.24M | (m) | 6.66× |
| 2025-03-31 | $217.32M | $28.49M | $29.42M | $179.05M | $88.00K | (m) | $3.87M | (m) | 7.63× |
| 2024-12-31 | $219.38M | $30.65M | $16.29M | $193.24M | $265.00K | (m) | $2.48M | (m) | 7.16× |
| 2024-09-30 | $237.43M | $32.16M | $31.97M | $196.21M | $184.00K | (m) | $2.70M | (m) | 7.38× |
| 2024-06-30 | $270.88M | $30.94M | $37.87M | $223.78M | $215.00K | (m) | $3.23M | (m) | 8.75× |
| 2024-03-31 | $304.51M | $29.02M | $49.40M | $244.59M | $917.00K | (m) | $5.94M | (m) | 10.49× |
| 2023-12-31 | $338.84M | $28.30M | $51.16M | $277.67M | $148.00K | (m) | $3.12M | (m) | 11.97× |
| 2023-09-30 | $350.69M | $24.57M | $104.06M | $234.43M | $1.13M | (m) | $2.38M | (m) | 14.27× |
| 2023-06-30 | $268.54M | $34.38M | $66.19M | $193.04M | $766.00K | (m) | $4.43M | (m) | 7.81× |
| 2023-03-31 | $239.49M | $27.10M | $52.74M | $175.79M | $1.53M | (m) | $2.65M | (m) | 8.84× |
| 2022-12-31 | $260.25M | $28.13M | $58.34M | $189.32M | $202.00K | (m) | $1.15M | (m) | 9.25× |
| 2022-09-30 | $306.92M | $28.81M | $82.08M | $211.28M | $397.00K | (m) | $1.23M | (m) | 10.65× |
| 2022-06-30 | $352.93M | $28.86M | $112.15M | $227.78M | $524.00K | (m) | $426.00K | (m) | 12.23× |
| 2022-03-31 | $368.01M | $26.67M | $147.63M | $206.10M | $374.00K | (m) | $1.81M | (m) | 13.80× |
| 2021-12-31 | $391.19M | $25.83M | $240.42M | $135.41M | $1.15M | (m) | $3.99M | (m) | 15.15× |
| 2021-09-30 | $449.05M | $26.16M | $435.31M | (m) | $578.00K | (m) | $3.48M | (m) | 17.17× |
| 2021-06-30 | $142.97M | $26.01M | $129.52M | (m) | $2.00K | (m) | $4.03M | (m) | 5.50× |
| 2020-12-31 | $24.31M | $12.39M | $15.95M | $0.00 | $150.00K | (m) | $2.60M | (m) | 1.96× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |